Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.

NCT03500484 · Terminated

Last updated 2026-05-28

This clinical trial tests how the medication liraglutide affects brain responses to sugary drinks in young adults with obesity.

Status Terminated Stopped early and will not restart.

Phase Early Phase 1 First exploratory testing in people.

Type Interventional (clinical trial)

Design Randomized, single-blind study

Participants 13 people

Who can join Ages 18–39 · all sexes Healthy volunteers accepted.

Timeline Started 2018-06 · est. completion 2020-06

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT03500484 ↗

Description as written by the study sponsor.

To study the effects of liraglutide on neural responses to high fructose corn syrup (HFCS) in individuals with obesity.

Liraglutide also known as Glucagon-like peptide 1 Drug

Liraglutide will be supplied in the following package sizes containing disposable, pre-filled, multidose pens. Each individual pen delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3 mg (6 mg/mL, 3 mL). Liraglutide will be self-administered daily for 12 weeks under the following regimen: 0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, 3.0mg until week 12.

Main thing measured	Brain Response in Obese Young Adults Who Drink Sugar Sweetened Beverages.
Sponsor	Yale University
Conditions studied	Obesity, Childhood, Neural Development
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03500484 ↗